|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||42.25 - 43.56|
|52 Week Range||38.05 - 58.79|
|PE Ratio (TTM)||27.59|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.00|
After reading BioSpecifics Technologies Corp’s (NASDAQ:BSTC) latest earnings update (31 December 2017), I found it beneficial to look back at how the company has performed in the past and compareRead More...
NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Adamis Pharmaceuticals (ADMP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.
Karyopharm Therapeutics (KPTI) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Flexion Therapeutics (FLXN) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Stock Monitor: BioSpecifics Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on Vericel Corp. (NASDAQ: VCEL ...
Madrigal Pharmaceuticals (MDGL) was a big mover last session, as the company saw its shares rise more than 6% on the day.
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
On a per-share basis, the Lynbrook, New York-based company said it had profit of 36 cents. Earnings, adjusted for pretax expenses, were 51 cents per share. The biopharmaceutical company posted revenue ...
LYNBROOK, N.Y. , March 14, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first ...
LYNBROOK, N.Y., March 12, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the presentation of interim data from its ongoing Phase 1 trial of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids at the 65th Annual Scientific Meeting of the Society for Reproductive Investigation on Friday, March 9, 2018 in San Diego, CA. The data show the safety and effectiveness of the CCH injection method in five patients. "These interim data are very encouraging and show not only a significant reduction of collagen content but also the disruption of the tissue pattern in the uterine fibroids injected with CCH," said Thomas L. Wegman, President of BioSpecifics.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo).
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biospecifics Technologies Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biospecifics Technologies Corp. Here are 5 ETFs with the largest exposure to BSTC-US. Comparing the performance and risk of Biospecifics Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Biospecifics Technologies Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Biospecifics Technologies Corp. – AbbVie, Inc., Horizon Pharma plc, Radius Health Inc, Abbott Laboratories, Eli Lilly and Company and Alder Biopharmaceuticals, Inc. (ABBV-US, HZNP-US, RDUS-US, ABT-US, LLY-US and ... Read more (Read more...)
BioSpecifics Technologies Corp (NASDAQ:BSTC) trades with a trailing P/E of 26.4x, which is lower than the industry average of 26.9x. Although some investors may jump to the conclusion that thisRead More...